Publicaciones en las que colabora con Anxo Fernández Ferreiro (43)

2024

  1. Biodistribution and pharmacokinetics of [89Zr]-anti-VEGF mAbs using PET in glioblastoma rat models

    International Journal of Pharmaceutics, Vol. 652

  2. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

    Pharmaceuticals, Vol. 17, Núm. 2

  3. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

    Pharmaceutics, Vol. 16, Núm. 1

2023

  1. Design and biopharmaceutical preclinical characterisation of a new thermosensitive hydrogel for the removal of gastric polyps

    International Journal of Pharmaceutics, Vol. 635, pp. 122706

  2. Efficacy and Safety of Inhaled Ethanol in Early-Stage SARS-CoV-2 Infection in Older Adults: A Phase II Randomized Clinical Trial

    Pharmaceutics, Vol. 15, Núm. 2

2022

  1. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

    Pharmaceutics, Vol. 14, Núm. 10

  2. PET study of intravitreal adalimumab pharmacokinetics in a uveitis rat model

    International Journal of Pharmaceutics, Vol. 627

2021

  1. Anti-inflammatory effect of tacrolimus/hydroxypropyl-β-cyclodextrin eye drops in an endotoxin-induced uveitis model

    Pharmaceutics, Vol. 13, Núm. 10

  2. Development and characterization of a tacrolimus/ hydroxypropyl-β-cyclodextrin eye drop

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-27

  3. Development and characterization of inhaled ethanol as a novel pharmacological strategy currently evaluated in a phase ii clinical trial for early-stage sars-cov-2 infection

    Pharmaceutics, Vol. 13, Núm. 3

  4. Feasibility of Longitudinal Brain PET with Real-Time Arterial Input Function in Rats

    Molecular Imaging and Biology, Vol. 23, Núm. 3, pp. 350-360

  5. In situ forming and mucoadhesive ophthalmic voriconazole/HPβCD hydrogels for the treatment of fungal keratitis

    International Journal of Pharmaceutics, Vol. 597

  6. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. -FMISO PET/MRI Imaging Shows Ischemic Tissue around Hematoma in Intracerebral Hemorrhage

    Molecular Pharmaceutics, Vol. 17, Núm. 12, pp. 4667-4675

  2. 3D printed tacrolimus rectal formulations ameliorate colitis in an experimental animal model of inflammatory bowel disease

    Biomedicines, Vol. 8, Núm. 12, pp. 1-19

  3. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  4. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  5. Características clínicas, manejo y resultados de los pacientes con endoftalmitis estéril asociados con la inyección intravítrea de factores de crecimiento endotelial antivascular

    Archivos de la Sociedad Española de Oftalmologia, Vol. 95, Núm. 5, pp. 211-216

  6. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

  7. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration

    International Journal of Pharmaceutics, Vol. 573